December 09, 2020
1 min watch
Jaeger, U et al. Abstract 1194. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Locke reports holding a scientific advisory role for Allogene, Celgene, GammaDelta Therapeutics, Kite, Novartis and Wugen; and acting as consultant with grant options for Cellular Biomedicine Group Inc.
Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center, discussed follow-up data from the JULIET trial presented at the ASH Annual Meeting and Exposition.
He talked about gauging therapy response with Myc expression
“Patients who had a high Myc expression by immunohistochemistry had worse outcomes. This is interesting because in the pivotal CAR T-cell therapy trials for diffuse large B-cell lymphoma, we haven’t seen that double hit lymphoma or double expressor lymphoma has really been a predictor for worse outcomes. Here, they quite simply looked by immunohistochemistry for Myc expression,” Locke told Healio in a video interview.